45 citations
,
July 2002 in “The Neurologist” This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.
20 citations
,
December 2016 in “Neurodegenerative disease management” This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.
284 citations
,
November 1999 in “Neurology” This article discusses the side effects of interferon beta therapy for MS, including flu-like symptoms and autoimmune reactions, and provides guidance on their management but does not report new clinical findings.
July 2023 in “Journal of skin and stem cell” In this study conducted at Baqiyatullah Hospital, it was found that interferon beta (IFNβ) treatment in multiple sclerosis patients commonly led to skin complications, with injection site erythema being most frequent, and also increased hair loss severity.
4 citations
,
May 2021 in “Biomedicines” This review explores the potential role of caveolin-1 in cicatricial alopecia, particularly frontal fibrosing alopecia, and discusses possibilities for targeted therapies without providing new research results.
